Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F. Minozzi S, et al. Among authors: marino v. Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783. Expert Opin Drug Saf. 2016. PMID: 27924643 Free article. Review.
Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F. Bonovas S, et al. Among authors: marino v. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54. doi: 10.1080/14740338.2016.1238458. Expert Opin Drug Saf. 2016. PMID: 27924644 Review.
Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
Ceccarelli F, Massafra U, Perricone C, Idolazzi L, Giacomelli R, Tirri R, Russo R, Pistone G, Ruscitti P, Parisi S, Sainaghi PP, Cacciapaglia F, Zullo A, Marino V, Migliore A, Valesini G. Ceccarelli F, et al. Among authors: marino v. Clin Exp Rheumatol. 2017 Jan-Feb;35(1):24-32. Epub 2016 Dec 9. Clin Exp Rheumatol. 2017. PMID: 27974105
Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M. Bonaccorso S, et al. Among authors: marino v. J Clin Psychopharmacol. 2002 Feb;22(1):86-90. doi: 10.1097/00004714-200202000-00014. J Clin Psychopharmacol. 2002. PMID: 11799348 Clinical Trial.
Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.
Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer HY, Maes M. Bonaccorso S, et al. Among authors: marino v. Psychiatry Res. 2001 Dec 15;105(1-2):45-55. doi: 10.1016/s0165-1781(01)00315-8. Psychiatry Res. 2001. PMID: 11740974 Clinical Trial.
421 results